Acurx Pharmaceuticals (NASDAQ:ACXP) Issues Earnings Results

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02, Zacks reports.

Acurx Pharmaceuticals Stock Performance

Shares of NASDAQ:ACXP opened at $0.41 on Wednesday. The stock has a market capitalization of $7.96 million, a price-to-earnings ratio of -0.37 and a beta of -1.71. Acurx Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $3.33. The company’s fifty day moving average is $0.71 and its two-hundred day moving average is $1.27.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Acurx Pharmaceuticals in a research note on Friday, January 10th.

Insiders Place Their Bets

In other Acurx Pharmaceuticals news, CEO David P. Luci bought 49,261 shares of the company’s stock in a transaction on Monday, January 6th. The shares were bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the acquisition, the chief executive officer now owns 1,097,458 shares of the company’s stock, valued at approximately $1,108,432.58. This trade represents a 4.70 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 29.60% of the stock is owned by corporate insiders.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.